Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Purpose: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of men with only lymph node metastasis (LNM) is u...

Full description

Bibliographic Details
Main Authors: William John Yaxley, Rhiannon McBean, David Wong, David Grimes, Paul Vasey, Mark Frydenberg, John William Yaxley
Format: Article
Language:English
Published: Korean Urological Association 2021-11-01
Series:Investigative and Clinical Urology
Subjects:
lutetium-177
lymphatic metastasis
prostate cancer
psma-617
Online Access:https://icurology.org/pdf/10.4111/icu.20210097

Internet

https://icurology.org/pdf/10.4111/icu.20210097

Similar Items